Detalhe da pesquisa
1.
Impaired nodal shrinkage and apoptosis define the independent adverse outcome of NOTCH1 mutated patients under ibrutinib therapy in chronic lymphocytic leukaemia.
Haematologica
; 106(9): 2345-2353, 2021 09 01.
Artigo
Inglês
| MEDLINE | ID: mdl-32732360
2.
Comparison of ibrutinib and idelalisib plus rituximab in real-life relapsed/resistant chronic lymphocytic leukemia cases.
Eur J Haematol
; 106(4): 493-499, 2021 Apr.
Artigo
Inglês
| MEDLINE | ID: mdl-33378569
3.
Effectiveness of ibrutinib as first-line therapy for chronic lymphocytic leukemia patients and indirect comparison with rituximab-bendamustine: Results of study on 486 cases outside clinical trials.
Am J Hematol
; 96(8): E269-E272, 2021 08 01.
Artigo
Inglês
| MEDLINE | ID: mdl-33878220
4.
TP53 disruption as a risk factor in the era of targeted therapies: A multicenter retrospective study of 525 chronic lymphocytic leukemia cases.
Am J Hematol
; 96(8): E306-E310, 2021 08 01.
Artigo
Inglês
| MEDLINE | ID: mdl-33989438
5.
Assessment of the 4-factor score: Retrospective analysis of 586 CLL patients receiving ibrutinib. A campus CLL study.
Am J Hematol
; 96(5): E168-E171, 2021 05 01.
Artigo
Inglês
| MEDLINE | ID: mdl-33580969
6.
CD69 is independently prognostic in chronic lymphocytic leukemia: a comprehensive clinical and biological profiling study.
Haematologica
; 97(2): 279-87, 2012 Feb.
Artigo
Inglês
| MEDLINE | ID: mdl-21993667
7.
TP53 Mutations with Low Variant Allele Frequency Predict Short Survival in Chronic Lymphocytic Leukemia.
Clin Cancer Res
; 27(20): 5566-5575, 2021 10 15.
Artigo
Inglês
| MEDLINE | ID: mdl-34285062
8.
Do age, fitness, and concomitant medications influence management and outcomes of patients with CLL treated with ibrutinib?
Blood Adv
; 5(24): 5490-5500, 2021 12 28.
Artigo
Inglês
| MEDLINE | ID: mdl-34525181
9.
Minimal residual disease as a biomarker for outcome prediction and therapy optimization in acute myeloid leukemia.
Expert Rev Hematol
; 11(4): 307-313, 2018 04.
Artigo
Inglês
| MEDLINE | ID: mdl-29495904
10.
Survival risk score for real-life relapsed/refractory chronic lymphocytic leukemia patients receiving ibrutinib. A campus CLL study.
Leukemia
; 35(1): 235-238, 2021 01.
Artigo
Inglês
| MEDLINE | ID: mdl-32286543